Results 151 to 160 of about 27,411 (201)

[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial. [PDF]

open access: yesEClinicalMedicine
Ferone D   +22 more
europepmc   +1 more source

Octreotide-Mediated Co-Solubilization of Paclitaxel and Docetaxel: A Novel Targeted Formulation for Synergistic Anticancer Chemotherapy. [PDF]

open access: yesPharmaceutics
Abdellatif AAH   +11 more
europepmc   +1 more source

What is the future of acromegaly therapy?

open access: yesJ Clin Endocrinol Metab
Schilbach K, Strasburger CJ.
europepmc   +1 more source

Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers. [PDF]

open access: yesJ Neuroendocrinol
Deroose CM   +8 more
europepmc   +1 more source

Current treatment landscape of acromegaly.

open access: yesJ Clin Endocrinol Metab
Castinetti F, Ioachimescu AG.
europepmc   +1 more source

Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis.

open access: yesJ Clin Endocrinol Metab
Salvatori R   +8 more
europepmc   +1 more source

Current controversies in acromegaly care.

open access: yesJ Clin Endocrinol Metab
Spencer-Segal JL, Nachtigall LB.
europepmc   +1 more source

Home - About - Disclaimer - Privacy